Nivolumab and Relatlimab-Rmbw
OPDUALAG
Programmed Death Receptor-1 Blocking Antibody
NADAC/unit
N/A
No Shortage
Nivolumab and Relatlimab-Rmbw helps the immune system fight cancer by blocking PD-1 immune checkpoints.
Market Intelligence
2025-10-29 Class II Recall: Bristol-Myers Squibb Company
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.